hydroxychloroquine / Generic mfg. - LARVOL DELTA

Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. (PubMed, Nat Med) - P2 | "We subsequently tested the effects of transient versus chronic inhibition of autophagy with chloroquine or hydroxychloroquine (HCQ) and mTOR signaling with rapamycin (RAPA) or everolimus (EVE) on residual tumor cell (RTC) burden and recurrence-free survival (RFS). These findings provide proof-of-concept that targeting dormant RTCs with HCQ, EVE or their combination in breast cancer survivors or mouse models depletes minimal residual disease, warranting a definitive human randomized controlled trial. ClinicalTrials.gov registration: NCT03032406 ."

Journal • P2 data • Breast Cancer • Oncology • Solid Tumor

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. (PubMed, J Immunother Cancer) - P1 | "REVOLUTION cohorts A and B demonstrated encouraging antitumor activity in patients with mPDAC. In cohort B, hydroxychloroquine-related tolerability issues contributed to early discontinuations and reduced drug exposure. These findings highlight the potential and limitations of current chemoimmunotherapy approaches. Although neither cohort will be expanded, the results reinforce the continued promise of chemoimmunotherapy in mPDAC and the importance of refining these strategies."

IO biomarker • Journal • P1 data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • ENTPD1 • PD-1

Choroidal thickness changes in patients with systemic lupus erythematosus treated with hydroxychloroquine using three dimensional maps. (PubMed, Int Ophthalmol) - "Patients with SLE treated with HCQ for one or more years present higher CT values than healthy subjects. Nasal zones seem to be the most sensitive to these changes, while the other choroidal locations remain similar apparently. However, neither duration of SLE nor duration or dose of HCQ treatment seemed to have any influence on CT."

Journal • Immunology • Inflammatory Arthritis • Lupus • Ophthalmology • Systemic Lupus Erythematosus

Case Report: Complete remission of Guillain-Barré syndrome in neuropsychiatric lupus with telitacicept. (PubMed, Front Immunol) - "Following inadequate response to intravenous immunoglobulin monotherapy, combination treatment was initiated with methylprednisolone (40mg daily), cyclophosphamide (0.6g biweekly), hydroxychloroquine, and telitacicept (160mg weekly), a novel dual inhibitor of B lymphocyte stimulator and a proliferation-inducing ligand that simultaneously targets B cells and plasma cells. Corticosteroids were successfully tapered to 4mg daily without disease flare. This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials."

Journal • CNS Disorders • Immunology • Inflammatory Arthritis • Lupus • Pain • Psychiatry • Systemic Lupus Erythematosus

Anti-CD19 Chimeric Antigen Receptor T-cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease (TCT-ASTCT-CIBMTR 2026) - "9 pts (37.5%) remained on AID tx at apheresis, including hydroxychloroquine (HCQ) (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol, sulfasalazine, and apremilast. In this study of CART for NHL we found no difference in clinical outcomes for pts with AID; we therefore propose that AID should not preclude the use of CART. The majority of pts were able to taper off AID tx prior to CART and HCQ was able to be safely continued throughout CART collection with no effect on efficacy. Our study also highlights the potential effect of CD19 directed CART on pt's AID given the majority of patients remained off AID tx for an extended time post-CART."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Impact of hydroxychloroquine on pregnancy outcomes in systemic lupus erythematosus: A 25 years retrospective cohort study from Asia. (PubMed, Lupus) - "The overall flare-up of disease was found in 68.8% (86/125), mostly in the third trimester. Positive anticardiolipin IgG antibodies were considerably higher in HCQ groups (47.25% vs 26.47%; p = .036).ConclusionOur study findings suggest that maintaining disease remission prior to conception and continuing HCQ therapy during pregnancy may be associated with improved maternal and fetal outcomes, though the observed association with fetal heart block warrants cautious interpretation due to small numbers."

Journal • Retrospective data • Gynecology • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Pembrolizumab-associated exacerbation of lichen planopilaris in a patient with metastatic melanoma. (PubMed, J Oncol Pharm Pract) - "LPP is an underrecognized follicular irAE. The timing, clinical course, and histopathologic findings suggest pembrolizumab-induced exacerbation. Causality was assessed using the Naranjo Algorithm, with a score of 6, indicating a probable adverse drug reaction. This case reinforces the importance of early recognition and tailored dermatologic care in patients receiving ICI therapy."

Journal • Alopecia • Immunology • Lichen Planus • Melanoma • Oncology • Solid Tumor

Pharmacological STING Activation Enhances Autophagy-Mediated Clearance of Mycobacterium tuberculosis in Human Macrophages. (PubMed, J Innate Immun) - "Activating the STING pathway with ADU-S100 is a potent host-directed strategy to bolster macrophage autophagy and enhance the elimination of intracellular Mtb. This provides a strong rationale for exploring STING agonists as a novel therapeutic intervention for tuberculosis, addressing a significant and clinically relevant challenge in infectious disease."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • STING

Hydroxychloroquine alleviates renal fibrosis by modulating dendritic cells glycolipid metabolism and its crosstalk with renal tubular epithelial cells. (PubMed, Eur J Pharmacol) - "Rescue experiments with PI3K agonist 740Y-P confirmed the involvement of downstream signaling. Collectively, HCQ alleviates RF by modulating DCs metabolism and impairing DCs-RTECs crosstalk, underscoring its therapeutic promise for RF."

IO biomarker • Journal • Chronic Kidney Disease • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • PD-L1

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov) - P1/2 | N=57 | Active, not recruiting | Sponsor: Pediatric Brain Tumor Consortium | Trial completion date: Jun 2030 ➔ Mar 2026 | Trial primary completion date: Mar 2027 ➔ Mar 2026

Trial completion date • Trial primary completion date • Brain Cancer • Genetic Disorders • Glioma • High Grade Glioma • Neurofibromatosis • Oncology • Solid Tumor

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. (PubMed, Oncologist) - P1/2 | "The combination of regorafenib, HCQ, and entinostat was poorly tolerated without evident activity in metastatic CRC."

Journal • P1 data • Colorectal Cancer • Fatigue • Gastrointestinal Cancer • Oncology • Solid Tumor

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ANTI-SYNTHETASE SYNDROME: LONG-TERM OUTCOMES FROM TWO REFRACTORY CASES (EBMT 2026) - "Over the following 18 months, he experienced multiple relapses despite sequential immunosuppressive strategies including mycophenolate mofetil, rituximab, ciclosporin, tacrolimus, and repeated corticosteroid pulses...Disease response to various treatments is summarised in Figure 1.Figure 1: Creatine Kinase trend with treatmentsCase 2A 46-year-old woman with Jo-1–positive ASSD initially responded to glucocorticoids, cyclophosphamide, and hydroxychloroquine but experienced multiple relapses requiring escalation to IVIg, tofacitinib, and rituximab...Two later flares were controlled with lower-dose prednisone, maintenance IVIg, and six-monthly rituximab... Our cases support ASCT as a viable option for selected ASSD patients amid growing interest in advanced cellular therapies such as CAR-T. While CAR-T shows promise, its long-term outcomes and accessibility remain uncertain. In contrast, ASCT offers multi-year follow-up data and comparatively lower cost, at approximately..."

Clinical • IO biomarker • Immunology • Interstitial Lung Disease • Myositis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Transplantation • CD4 • CD8

Study on the Safety and Efficacy of Anlotinib Combined with Hydroxychloroquine in the Treatment of Non-Small Cell Lung Cancer (ChiCTR) - P1/2 | N=60 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report. (PubMed, BMC Ophthalmol) - "This case illustrates CMV retinitis in the setting of JAK inhibition complicated by delayed retinal ischemia and vitreous hemorrhage arising remote from the original retinitis. Although ischemic vasculopathy is a recognized complication of CMV retinitis among non-HIV immunosuppressed patients, such sequelae have been infrequently documented in JAK inhibitor-associated cases. Ophthalmologists should maintain a high index of suspicion for CMV retinitis in this emerging population and continue close surveillance for delayed ischemic complications even after apparent disease stabilization."

Journal • Achromatopsia • Cardiovascular • Cytomegalovirus Infection • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Rheumatoid Arthritis • Rheumatology • Uveitis

Whipple's Disease: A Diagnostic Challenge in Patients With Chronic Diarrhea. (PubMed, Cureus) - "The patient was treated with ceftriaxone for two weeks, followed by a year of doxycycline and hydroxychloroquine, leading to rapid clinical remission. Due to ongoing histological changes, antibiotic therapy was continued for another year with trimethoprim-sulfamethoxazole and an additional six months of doxycycline...This case demonstrates the importance of maintaining a high index of suspicion and performing repeat endoscopic evaluation if symptoms continue despite unremarkable initial findings. Timely administration of suitable antibiotic therapy is associated with favorable clinical outcomes, even in cases with prolonged or atypical presentations."

Journal • Fatigue • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Rheumatology • CD68

ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment. (PubMed, bioRxiv) - P1 | "We have previously shown that the combination of GPH (gemcitabine, paricalcitol, and hydroxychloroquine) influences PDAC TME. Targeting integrin αvβ3 using ProAgio modulates the PDAC TME by improving perfusion, reducing hypoxia, reversing EMT, and alleviating immune suppression. ProAgio potentiates the effects of GPH therapy, which should be evaluated in future trials."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CAFs • CD4

Case Report: Telitacicept exposure in early pregnancy in a patient with SLE delivering an infant without any physical defect. (PubMed, Front Med (Lausanne)) - "The use of biologics is not recommended during pregnancy in SLE patients; belimumab or rituximab may be considered selectively only during lactation...During gestation, she was maintained on oral glucocorticoids, hydroxychloroquine, and tacrolimus. On 23 June 2025, at 32 weeks of gestation, she underwent a cesarean section due to "intrauterine growth restriction and preeclampsia" and delivered a male infant without any physical defects. This case suggests that exposure to telitacicept in the early stage of pregnancy did not result in structural defects in this case."

Journal • Gynecology • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

APLAQUINE: Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome (clinicaltrials.gov) - P2 | N=25 | Completed | Sponsor: University Hospital, Rouen | Unknown status ➔ Completed

Trial completion • Genetic Disorders • Hematological Disorders

Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses (SSWC 2026) - No abstract available

Immunology • Scleroderma • Systemic Sclerosis

Pentoxifylline as a Steroid-Sparing Agent in Granuloma Annulare: A Rural Retrospective Study. (PubMed, J Drugs Dermatol) - "Generalized GA is more treatment-resistant and associated with a greater comorbidity burden. Pentoxifylline demonstrated favorable efficacy and may serve as a first-line systemic agent in refractory cases. Further multi-center studies are needed to validate these findings and guide evidence-based management of GA. &nbsp."

Journal • Retrospective data • Dermatology • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Pediatrics • Rare Diseases • Type 2 Diabetes Mellitus

Parallel improvement of chorea and antiphospholipid autoimmunity during combination therapy with hydroxychloroquine, belimumab and glucocorticoids in systemic lupus erythematosus. (PubMed, Mod Rheumatol Case Rep) - "Treatment options include anticonvulsants, dopamine antagonists, antiplatelets, anticoagulants, and immunosuppressants such as cyclophosphamide; however, no specific treatment has been established. A systematic literature review revealed no previously reported cases of chorea associated with SLE treated with a combination of hydroxychloroquine and belimumab. Our case suggests this combination therapy may have a role in maintaining remission and modulating antiphospholipid autoimmunity of SLE-associated chorea."

Journal • Immunology • Inflammatory Arthritis • Lupus • Movement Disorders • Systemic Lupus Erythematosus

Impact of Hydroxychloroquine on Mortality and Cardiovascular Outcomes in Systemic Sclerosis: A Retrospective Cohort Study. (PubMed, Int J Rheum Dis) - "Our research indicated that although patients on HCQ had a higher prevalence of PH, they exhibited lower mortality rates, suggesting a possible survival benefit. Further prospective studies are needed to explore these findings and clarify HCQ's role in SSC management."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Coronary Artery Disease • Heart Failure • Hypertension • Immunology • Inflammation • Myocardial Infarction • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

HCQ in Resectable Localized Prostate Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Lionel.D.Lewis, MD | Not yet recruiting ➔ Recruiting

Enrollment open • Tumor mutational burden • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

An Association Between Autoimmune Hepatitis (AIH) and Immunoglobulin G4-Related Disease (IgG4-RD) in a Male Diagnosed With Primary Sjögren's Syndrome (SJS): A Case-Based Review. (PubMed, Cureus) - "Treatment with prednisolone, hydroxychloroquine, and azathioprine brought about clinical and biochemical improvement. Rituximab was contemplated for escalated therapy due to the overlapping autoimmune conditions and systemic nature of IgG4-RD...It is essential to differentiate IgG4-AIH from classic AIH or pSS-related liver disease, as it may have a different treatment response and prognosis. Further studies would assist in refining the diagnostic criteria and therapeutic strategies for overlapping autoimmune syndromes."

Journal • Autoimmune Hepatitis • Cholestasis • Diabetes • Endocrine Disorders • Fibrosis • Hepatitis C • Hepatology • Immunology • Inflammation • Metabolic Disorders • Sjogren's Syndrome • Type 2 Diabetes Mellitus